Battered Discovery Labs tries to reassure investors

Discovery Laboratories is signaling investors to hang on for a few weeks more. After seeing its stock price go into meltdown mode Friday on the FDA's third approvable letter for Surfaxin, Discovery execs announced that they believe they can respond to the agency in six to eight weeks and may get another review in as few as 60 days.

"Discovery Labs firmly believes that this recent approvable letter reflects notable progress towards gaining FDA approval for Surfaxin," the company said on Monday. There is no requirement for a new trial of the drug, which treats respiratory distress syndrome in premature babies. Discovery Labs may be making an impact. Its stock price climbed more than 10 percent this morning.

- check out the Discovery release

Related Articles:
FDA delays Discovery Labs approval
Discovery Labs to raise $25M
Discovery Labs to explore "strategic alternatives"
Discovery Labs pulls marketing app for Surfaxin
Discovery Labs shares sink on data demand

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.